# A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy

> **NCT04629248** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Hoffmann-La Roche** · enrollment: 142 (actual)

## Conditions studied

- Primary Membranous Nephropathy

## Interventions

- **DRUG:** Obinutuzumab
- **DRUG:** Tacrolimus
- **DRUG:** Methylprednisolone
- **DRUG:** Acetaminophen
- **DRUG:** Diphenhydramine

## Key facts

- **NCT ID:** NCT04629248
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-06-25
- **Primary completion:** 2025-12-22
- **Final completion:** 2027-12-21
- **Target enrollment:** 142 (ACTUAL)
- **Last updated:** 2026-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04629248

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04629248, "A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04629248. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*